Supernus Pharmaceuticals filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company focused on central nervous system diseases. Recent Form 8-K reports cover operating results, conference-call related earnings releases, material definitive agreements, executive compensation arrangements, and other material events tied to the company's CNS product portfolio and corporate obligations.
Proxy materials describe annual meeting voting matters, director elections, advisory executive compensation votes, auditor ratification, and equity incentive plan amendments. The filings also identify the company's common stock structure, exchange listing, shareholder voting mechanics, governance practices, and capital-structure disclosures.
Supernus Pharmaceuticals, Inc. executive Frank Mottola, SVP and Chief Technical Operations Officer, reported the acquisition of 1,650 Performance Share Units on July 29, 2026.
The units relate to an award granted on February 19, 2025 that vests upon achievement of individual performance objectives established on May 3, 2025. Following this transaction he holds 1,650 units directly, each corresponding to one share of common stock.
SUPERNUS PHARMACEUTICALS, INC. reported that Sr. VP of IP, CSO Padmanabh P. Bhatt acquired 2,500 Performance Share Units on July 29, 2026. These units, each tied to one share of Common Stock and granted at $0.00, relate to an award made on February 19, 2025 that vested upon achieving individual performance objectives established on May 3, 2025. Following this award, Bhatt holds 2,500 Performance Share Units directly.
SUPERNUS PHARMACEUTICALS, INC. reported that SVP and Chief Medical Officer Jonathan Rubin acquired 750 Performance Share Units on July 29, 2026. These units are a portion of an award granted on February 19, 2025 that vested upon achievement of individual performance objectives established on May 3, 2025 and are tied to 750 shares of common stock.
Supernus Pharmaceuticals, Inc. plans to report its second quarter 2026 financial and business results after the market closes on Tuesday, August 4, 2026. The company will host a conference call and webcast that day at 4:30 p.m. ET to review the results and take questions.
The live webcast will be available in the Events & Presentations section of the company’s investor relations website, with registration providing dial-in details. A replay of the call will remain accessible on the site for 60 days. Supernus describes itself as a biopharmaceutical company focused on developing and commercializing treatments for a range of central nervous system diseases, including ADHD, Parkinson’s disease-related conditions, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea.
Supernus Pharmaceuticals, Inc. reported the results of its 2026 annual stockholder meeting, where all four proposals received the required support. Stockholders elected Class I directors Frederick M. Hudson and Charles W. Newhall, III to terms ending at the 2029 annual meeting.
Stockholders approved, on a non-binding basis, the compensation of the company’s named executive officers and ratified KPMG LLP as independent public accounting firm for the fiscal year ending December 31, 2026. They also approved an amendment to the 2021 Equity Incentive Plan to increase the number of shares available under the plan. There were 58,039,721 shares of common stock outstanding and entitled to vote as of April 29, 2026.
Supernus Pharmaceuticals, Inc. has become obligated to pay a milestone under its Contingent Value Rights Agreement after Milestone 1 was achieved on March 18, 2026. The payment is equal to $0.50 per Contingent Value Right (CVR), for an aggregate of approximately $33.4 million.
The milestone payment will be made in cash, without interest and subject to applicable withholding taxes. Supernus will deposit the funds with the rights agent within 20 business days of May 17, 2026, and the rights agent will distribute payments to CVR holders under the terms of the CVR Agreement.
Supernus Pharmaceuticals reported strong growth for the first quarter of 2026, with total revenues of $207.7 million, up 39% from $149.8 million a year earlier. Revenues from commercial products, including collaboration revenue from ZURZUVAE, reached $178.4 million, a 26% increase.
Growth was driven by key CNS products: Qelbree net sales rose 20% to $77.9 million, GOCOVRI grew 15% to $35.2 million, ONAPGO generated $8.4 million after launch, and ZURZUVAE collaboration revenue contributed $27.6 million. The company posted a GAAP net loss of $2.3 million (or $0.04 per share), narrowed from $11.8 million, while non-GAAP adjusted operating earnings improved to $28.7 million. Cash, cash equivalents, and current marketable securities increased to $384.2 million as of March 31, 2026. Supernus reiterated its full-year 2026 guidance, including total revenues of $840–$870 million and non-GAAP adjusted operating earnings of $140–$170 million.
Supernus Pharmaceuticals, Inc. will hold its 2026 Annual Meeting of Stockholders virtually on June 18, 2026 at 10:00 A.M. EDT. Stockholders will vote on electing two directors for three-year terms, an advisory say-on-pay resolution, ratifying KPMG LLP as auditor for 2026, and amending the 2021 Equity Incentive Plan to increase available shares. The record date is April 29, 2026, when 58,039,721 common shares were outstanding, each entitled to one vote. The proxy also details board composition, committee structures, director and executive biographies, ownership of major stockholders and insiders, and Supernus’ executive compensation philosophy emphasizing pay-for-performance and alignment with stockholder interests.